IRMD - アイラディメッド （iRadimed Corporation）

Letter Notifying Customers of Potential Issues with MRidium 1057 MRI Syringe Adapter Set Letter Notifying Customers of Potential Issues with MRidium 1057 MRI Syringe Adapter Set

IRadimed came in with a strong set of Q4 and full-year numbers. Click here to read more about IRMD stock.

IRadimed reported strong Q4:22 results, essentially driven by strength in its monitors segment. See why we reiterate IRMD stock as a buy.

https://www.investing.com/news/pro/iradimed-corp-pt-raised-to-51-at-singular-research-432SI-2996393

IRadimed Corporation (NASDAQ:NASDAQ:IRMD) Q4 2022 Earnings Conference Call February 2, 2023 11:00 AM ETCompany ParticipantsRoger Susi - President & CEOJack Glenn – CFOConference Call…

IRadimed Corporation (NASDAQ:NASDAQ:IRMD) Q4 2022 Earnings Conference Call February 2, 2023 11:00 AM ETCompany ParticipantsRoger Susi - President & CEOJack Glenn – CFOConference Call…

iRadimed press release (IRMD): Q4 Non-GAAP EPS of $0.32 (vs

iRadimed (NASDAQ:IRMD) declares $1.05/share special dividend.Payable Feb. 21; for shareholders of record Feb. 13; ex-div Feb.

WINTER SPRINGS, Fla., Feb. 02, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ: IRMD) announced today its financial results for the fourth quarter and year ended December 31, 2022. The Company also announced that its Board of Directors approved a special cash dividend of $1.05 per share on the Company''s outstanding common stock. This special cash dividend is payable on February 21, 2023, to shareholders of record at the close of business on February 13, 2023. The Company is a leader in the development of innovative magnetic resonance imaging ("MRI") medical devices and the only known provider of a non-magnetic intravenous ("IV") infusion pump system and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.

iRadimed (NASDAQ: IRMD ) is set to give its latest quarterly earnings report on Thursday, 2023-02-02. Here''s what investors need to know before the announcement. Analysts estimate that iRadimed will report an earnings per share (EPS) of $0.28. iRadimed bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next … Full story available on Benzinga.com

According to Benzinga Pro, during Q3, iRadimed (NASDAQ: IRMD ) earned $3.43 million, a 5.74% increase from the preceding quarter. iRadimed also posted a total of $13.41 million in sales, a 5.38% increase since Q2. In Q2, iRadimed earned $3.24 million, and total sales reached $12.72 million. Why Is ROCE Significant? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of … Full story available on Benzinga.com

iRadimed continues to re-rate to the downside despite robust fundamentals last quarter.

https://www.investing.com/news/pro/iradimed-corp-pt-raised-to-45-at-singular-research-432SI-2935721

IRadimed Corporation (NASDAQ:NASDAQ:IRMD) Q3 2022 Earnings Conference Call November 03, 2022 11:00 AM ET Company Participants Roger Susi - President and Chief Executive Officer Jack Glenn -…

iRadimed (NASDAQ: IRMD ) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings iRadimed beat estimated earnings by 20.83%, reporting an EPS of $0.29 versus an … Full story available on Benzinga.com